cetuximab,adagrasib
Mirati,eli lilly
['cetuximab', 'krystal 1', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'adagrasib']
promising results of adagrasib plus cetuximab in heavily pretreated pts with kras g12c-mutated crc. orr 46%, dcr 100%, mpfs 6.9 months. ongoing phase iii trial in the second line setting (krystal 10). dual blockade of the pathway seems the way to go! #esmo2022 #paris
28. MD. PhD student. Medical Oncology trainee at Ramón y Cajal University Hospital (Madrid). ES ????| EN ????| FR ????| ZH ????| ???? ??Avid traveller! ????